Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement

Yonsei University logo

Yonsei University

Status and phase

Completed
Phase 4

Conditions

Abnormal Aortic Valve

Treatments

Drug: ulinastatin

Study type

Interventional

Funder types

Other

Identifiers

NCT00944385
4-2009-0079

Details and patient eligibility

About

According to TEG (thromboelastography), as maximum amplitude is increased the amount of bleeding and transfusion and Cardiac enzyme is reduced by using ulinastatin.

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • 40% below of output of left ventricle
  • tricuspid valve failure from moderate to severe
  • urgent surgery required
  • infectious endocarditis

Trial design

0 participants in 2 patient groups, including a placebo group

ulinastatin
Experimental group
Description:
Administer with 30,000U /ulinastatin
Treatment:
Drug: ulinastatin
C group
Placebo Comparator group
Description:
administer normal saline
Treatment:
Drug: ulinastatin

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems